Product Description
The global atherectomy device market was valued at $915 million in 2025. This is expected to increase over the forecast period at a CAGR of 1.3% to reach $1 billion by 2032.
The full report on the global market for atherectomy devices includes laser atherectomy devices and mechanical atherectomy devices.
The report includes data for 65 countries across 7 different regions which include North America, Latin America, Western Europe, Central & Eastern Europe, Middle East, Asia-Pacific, and Africa.
Data Types Included
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2032, and Historical Data to 2022
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Atherectomy Device Market Trends
The intravascular atherectomy market is currently witnessing a significant shift toward minimally invasive and precision-based approaches, driven by technological advancements and growing demand for improved patient outcomes. The trend is marked by the development of next-generation atherectomy devices that offer enhanced navigational capabilities, real-time imaging guidance and improved plaque removal efficiency. This emerging trend is fostering a transition from traditional surgical methods toward more targeted and efficient intravascular interventions, ultimately contributing to the market’s expansion and improved treatment options for patients with atherosclerosis.
Atherectomy Device Market Share Insights
- Abbott Vascular was the leading competitor in the peripheral atherectomy device market in 2025. The company strengthened its position in April 2023 through the acquisition of Cardiovascular Systems, Inc. (CSI), which offers the Diamondback 360® and Stealth 360® peripheral atherectomy systems. The Diamondback 360®, a traditional rotablator system, incorporates design improvements aimed at reducing procedural side effects such as restenosis and vessel perforation. It is approved for both above-the-knee (ATK) and below-the-knee (BTK) procedures, with particularly strong adoption in the BTK segment. The average number of Diamondback 360® devices used per procedure is also higher than the industry average.
- Medtronic’s presence in the intravascular atherectomy device market has been shaped by strategic acquisitions, including Covidien and ev3. Covidien’s acquisition of ev3 in 2010 elevated it as the market leader, building on ev3’s previous dominance since 2007 through its acquisition of FoxHollow’s SilverHawk™ line. SilverHawk™ utilizes rotating blade shavers, capable of removing 100 mg of plaque and clearing blockages up to 8 mm in diameter, especially suited for ATK procedures. Covidien’s product portfolio saw advancements like SilverHawk™ EXL for BTK treatment and Food and Drug Administration (FDA) approval for the TurboHawk™ system, addressing BTK challenges. In Medtronic’s 2025 revenue, HawkOne™ led in the hospital market, followed by TurboHawk™, with SilverHawk™ being the most affordable option.
- Philips entered the laser atherectomy market in 2017 after the acquisition Spectranetics with CVX-300 Excimer® and the Nexcimer Laser System, along with the Turbo® catheter line. Turbo-Elite® led in terms of revenue, in which Turbo-Power® also contributed, commanding a premium in 2025. Philips’ adaptable Turbo-Elite® lasers boosted the market, especially in outpatient labs. The high ASP of CVX-300 Excimer® led to rentals due to substantial investment, limiting adoption versus standalone devices. Philips expanded its laser atherectomy base in 2022. With the unique ability to address both soft plaque and calcium using laser and mechanical tools, Philips holds a competitive edge that is yet to be fully harnessed.
Atherectomy Device Market Segmentation Summary
- Laser Atherectomy Device Market
- Mechanical Atherectomy Device Market
Research Scope Summary
| Report Attribute | Details |
|---|---|
| Regions | North America (Canada, United States) Latin America (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom) Central & Eastern Europe (Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Malaysia, Mongolia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam) Africa (Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2025 |
| Forecast | 2026-2032 |
| Historical Data | 2022-2024 |
| Quantitative Coverage | Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.
